The ICMR might revise its recommendation on hydroxychloroquine (HCQ) for treatment of COVID-19 patients following doubts over its efficacy. India is the world’s largest producer of this anti-malarial drug, which is also used to treat auto-immune disorders. HCQ has failed two controlled trials in China and France.